FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication
Year: 2017
Type: article
Source: Case Medical Research
Author: U.S. Food & Drug Administration
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4243752273
